Aspira Women's Health Inc. (AWHL): Nasdaq/NYSE listing notice — Aspira Women's Health gets 180-day Nasdaq extension to May 2023 to cure $1 bid price deficiency

Aspira Women's Health Inc.

Received Nasdaq notice granting 180-day extension until May 29, 2023, to meet minimum $1.00 bid price requirement.
Initial cure period ended Nov 28, 2022, without compliance; extension granted due to intent to effect a reverse stock split.
If not compliant by May 29, 2023, Nasdaq will delist; company may appeal to a hearing panel.
Company must achieve closing bid price of $1.00 for 10 consecutive business days to regain compliance.
Common stock listed on Nasdaq under symbol AWH.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Aspira Women's Health Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

November 29, 2022, Aspira Women’s Health Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) that the Company has been granted an additional 180 calendar days, or until May 29, 2023 (as the first trading day following such period), to regain compliance with the minimum closing bid price of $1.00 per share, as is required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). As the Company previously reported on that cert

View on SEC.gov

2 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Aspira Women's Health Inc. filing history →

Source: SEC EDGAR

accession 0000926617-22-000064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.